Association between the composite CRP–TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis - Summary - MDSpire
Advertisement
Association between the composite CRP–TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis
To evaluate the association between the CRP–TyG composite index and the risk of incident malignancy in hospitalized patients with diabetes, emphasizing potential nonlinear effects and their clinical significance.
Key Findings:
344 incident malignancies documented during follow-up.
Malignancy risk increased progressively across CRP–TyG quartiles; highest quartile showed HR = 1.92 (95% CI: 1.42–2.60) compared to lowest quartile.
Significant nonlinear association with an inflection point at a CRP–TyG z-score of 0.62.
Composite index demonstrated better discriminatory performance than CRP or TyG alone, particularly for gastrointestinal cancers.
Interpretation:
The CRP–TyG composite index is independently associated with increased malignancy risk in hospitalized diabetic patients, exhibiting a nonlinear dose–response relationship, which may inform clinical risk stratification.
Limitations:
Retrospective design may introduce biases that could affect the results.
Potential confounding factors not fully accounted for.
Generalizability may be limited to similar inpatient populations.
Conclusion:
The CRP–TyG composite index may serve as a simple biomarker for early malignancy risk stratification in hospitalized patients with diabetes, highlighting its potential role in diabetes management.
In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response...
Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen screening is low in younger men—but rises sharply with age.
On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive earl...
